ASCO Abstracts 2020 | axi cel, gsk3359609, atezo bev hcc, keynote 204, ino 5401
ASCO: axi-cel in ZUMA-1
Abstract No : 8012
Abstract Type : Oral Abstract Session
Indication : Diffused Large B-Cell Lymphoma (DLBCL)
Intervention : Yescarta
Company : Kite, a Gilead Company
Technology : CAR T Cell Therapy
Based on this limited sample size, reTx with axi-cel may
have clinical efficacy, although transient, in some pts, especially those who
achieve CR with 1st Tx. CAR T cell expansion and severe CRS and NEs may be
attenuated at reTx. Further studies with additional pts are needed to confirm
these results.
View More: https://www.delveinsight.com/asco-conference/article/zuma-1
GSK: Cell Therapy and Next-generation Immuno-oncology
At this year’s ASCO meeting, they will showcase
presentations on investigational therapies, including belantamab mafodotin, an
antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for
patients with head and neck cancer.
IMbrave150 TRIAL of Atezolizumab
IMbrave150 demonstrated statistically significant and
clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in
pts with unresectable HCC who have not received prior systemic therapy. Pts
achieved CRs regardless of poor prognostic factors or etiology. Atezo + bev may
be a practice-changing treatment for pts with unresectable HCC.
View More: https://www.delveinsight.com/asco-conference/article/imbrave150
ASCO: KEYNOTE-204
Abstract No : 8005
Abstract Type : Oral Abstract Session
Indication : Hodgkin’s Lymphoma (HL)
Intervention : Pembrolizumab
Company : Merck Sharp & Dohme Corp., a
subsidiary of Merck & Co.
Technology : Immunocheckpoint
In pts with R/R cHL, pembro was superior to BV and
demonstrated statistically significant and clinically meaningful improvement in
PFS across all subgroups, with safety consistent with previous reports. Pembro
monotherapy should be standard of care for this pt population with R/R/cHL.
View More: https://www.delveinsight.com/asco-conference/article/NCT02684292
ASCO: INO-5401 + INO-9012 with Cemiplimab
Abstract No : 2514
Abstract Type : Oral Abstract Session
Indication : Glioblastoma Multiforme
Intervention : INO-5401 and INO-9012 +
Cemiplimab
Company : Inovio Pharma
Technology : T cell therapy/Monoclonal Antibody
INO-5401 + INO-9012 in combination with cemiplimab and
RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival
advantage in patients with newly-diagnosed GBM.
View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683
Comments
Post a Comment